Silica MSDS: How to Read It and What Safety Information to Check

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica for 3D Printing: Uses in Resins, Powders and Binder Jetting
  • Keywords: Nouryon Levasil
  • Published: 2026-11-20 10:23:36
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Feng, L., Dong, Z., Tao, D., Zhang, Y. & Liu, Z. The acidic tumor microenvironment: a target for intelligent cancer nano-theranostics. Natl Sci. Rev. 5, 269-286 (2018). Article CAS Google Scholar

Silica in Makeup Powder: Benefits for Oil Absorption and Blurring Effects

Silicon Dioxide CAS 7631-86-9: Identification, Properties and Regulatory Information
Saikia, D., Deka, J. R., Wu, C.-E., Yang, Y.-C. & Kao, H.-M. pH responsive selective protein adsorption by carboxylic acid functionalized sizable pore mesoporous silica nanoparticles SBA-1. Mater. Sci. Eng. C. 94, 344-356 (2019). Post CAS Google Scholar
Silica Bulk Density: Typical Values by Type and Why It Matters for Handling
Kadria-Vili, Y. et al. Gd 2 O 3 -mesoporous silica/gold nanoshells: a potential dual T 1 /T 2 contrast agent for MRI-guided localized near-IR photothermal therapy. Proc. Natl Acad. Sci. USA 119, e2123527119 (2022). Post CAS PubMed Central PubMed Google Scholar
Fumed Silica Manufacturer: Production Process, Key Grades and How to Choose
Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
What Is Silica? Definition, Main Types, Key Properties and Industrial Uses (2026 Guide)
H.L. and R.S. conceived and revised the paper, B.X. drew the figures and wrote the paper, S.L. collected the data and wrote the paper. All the authors have read and approved the paper.

Silica for Underfill: Submicron Spherical Silica Requirements and Selection

What is silica (SiO₂)?

silica sand With the rapid expansion of nanotechnology, nanomaterials have demonstrated great promise in the biomedical field due to their outstanding physicochemical properties. A variety of nanoformulations have been widely explored and developed for cargo delivery, 1, 2, 3, 4, 5 sickness diagnosis, 6, 7, 8, 9 and therapeutic purposes. 10, 11, 12, 13 Compared to macroscale counterparts, nanoformulations always enjoy the distinctive merits, including higher bioavailability, cut down toxic effects and boosted selectivity, in the living organism. 14 Typically, nanoformulations contain two major categories: organic and inorganic nanoformulations. 14, 15 Organic ones such as liposomes and polymers have been demonstrated to be a really effective and secure class of drug carriers, as evidenced by the fact that Doxil l is the first American Food and Drug Administration (FDA)-approved nanoliposomal drug formulation, 16 and the recently reported development of two lipid nanoparticles (NPs)-based COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273). 17 For inorganic NPs-based formulations, though they are slightly inferior to organic NPs-based formulations in terms of biocompatibility and safety, they are superior to organic NPs-based formulations in terms of stability and drug delivery efficiency. Importantly, some distinctive properties possessed by inorganic NPs such as optical, ultrasonic, magnetic and catalytic properties have given rise to some novel NPs-based therapies, i.e., photothermal therapy (PTT), 18, 19 photodynamic therapy (PDT), 20, 21 sonodynamic therapy (SDT), 22, 23 chemodynamic therapy (CDT) 24, 25 and nanozyme-based catalytic therapy. 26, 27 Encouragingly, inorganic NPs are also steadily moving to the clinical stage, with about 25 inorganic nanomedicines approved for clinical use. 28

What is the difference between fumed silica and precipitated silica?

hollow glass microspheres Liu, J. et al. Controlled synthesis of uniform and monodisperse upconversion core/mesoporous silica shell nanocomposites for bimodal imaging. Chem. Eur. J. 18, 2335-2341 (2012). Article CAS PubMed Google Scholar

What drives silica raw material prices?

silicosis Wang, X., Li, X., Ito, A., Sogo, Y. & Ohno, T. Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy. Acta Biomater. 9, 7480-7489 (2013). Article CAS PubMed Google Scholar

Cite this article: Silica Raw Materials News. "Silica Supply Chain: Raw Materials, Production Hubs and Risks ." Published 2026-11-20 10:23:36. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.